Outlook Therapeutics
OTLK
63 hedge funds and large institutions have $45.9M invested in Outlook Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 8 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
0.03% more ownership
Funds ownership: 0.58% → 0.61% (+0.03%)
0% more funds holding
Funds holding: 63 → 63 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
9% less capital invested
Capital invested by funds: $50.2M → $45.9M (-$4.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.32M |
| 2 |
Renaissance Technologies
New York
|
+$615K |
| 3 |
State Street
Boston,
Massachusetts
|
+$536K |
| 4 |
Goldman Sachs
New York
|
+$339K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$268K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.49M |
| 2 |
Two Sigma Advisers
New York
|
-$931K |
| 3 |
Axa
Paris,
France
|
-$404K |
| 4 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$179K |
| 5 |
Jane Street
New York
|
-$160K |
OTLK Hedge Fund Activity: Q3 2021 in Review
63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2021, worth a combined $45.9M — down 8.6% from $50.2M a quarter earlier.
Fund positioning in OTLK was balanced in Q3 2021: 8 funds opened new positions, 8 closed out, 25 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.32M. The largest seller was Two Sigma Investments, cutting an estimated $1.49M.
- 63 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $45.9M of Outlook Therapeutics stock for Q3 2021, down 8.6% quarter-over-quarter.
- 8 funds opened new Outlook Therapeutics positions in Q3 2021 and 8 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics buyer in Q3 2021 was Millennium Management, an estimated $2.32M added.
- The largest Outlook Therapeutics seller in Q3 2021 was Two Sigma Investments, an estimated $1.49M sold.
Based on aggregated 13F filings for Q3 2021.